A well-deserved lab night out!
Presenting Novel Discoveries from the Nik Lab at the 2025 SITC Annual Meeting and Receiving a SITC Young Investigator Travel Award
Relentless innovation to improve lives
A new cancer immunotherapy candidate's powerful dual mechanism of action
Revolutionizing Cancer Treatment: Dual-Action Immunotherapy Candidate Shows Promise
New findings from the lab presented at the 2025 SITC Annual Meeting, where Dr. Ebrahimi-Nik received one of 40 Young Investigator Travel Awards.
Relentless innovation to improve lives
A new cancer immunotherapy candidate's powerful dual mechanism of action
A groundbreaking immunotherapy candidate, now in clinical trials, offers a powerful dual response against cancer. This small molecule increases the activity of immune cells while making tumors more susceptible to immune attack. Developed by researchers at the Broad Institute, AbbVie, and Calico Life Sciences, the drug targets proteins that inhibit immune cell activation, enhancing the body's ability to fight cancer. This innovative approach, distinct from existing therapies, could significantly improve treatment outcomes without the need for combination with other drugs. For more details, visit the Broad Institute's announcement.